Kyorin pharmaceutical products. ” on April 2023.


  1. Kyorin pharmaceutical products. In Japan, KYORIN and Kissei Pharmaceutical Co. To ensure the stable supply of high-quality product, Kyorin Group complies with laws and regulations, and ensures liability, quality assurance and safety management. KYORIN Pharmaceutical Group Facilities provides stable supplies of highly reliable products with an awareness of low-cost operations, having three plants as manufacturing centers by giving unique capabilities for overall optimization of all manufactured products and appropriate capital investment. Going forward, KYORIN Pharmaceutical Co. , have been co-marketing the same product under the brand name of "Beova ® Tablets 50mg" since November 2018. This content provides drug business developed by KYORIN Pharmaceutical, KYORIN Rimedio and KYORIN Pharmaceutical Group Facility. It also provides solutions to medical professionals in infection-related fields. Jul 31, 2025 · Products Under Development Top R&D Products Under Development As of July 31, 2025 We will taken on the challenge of “drug discovery innovation” to create new value by combining drug discovery technologies and disease research. This section provides information on the long-term vision, medium-term business plan, financial and performance results, IR library and stock. has a proven track record in providing solutions to medical professionals in infection-related fields, offering information and proposals Mar 6, 2023 · KYORIN has the exclusive rights to develop, manufacture, and commercialize the Compound in Japan and Asian countries *. . List of 46 Japanese ethical pharmaceuticals whose manufacturer is KYORIN Pharmaceutical Co. KYORIN Holdings, Inc. Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin that could be worth hundreds of Kyorin markets its products under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. All of the products we offer carry with them our wish for a "smiley society. Nov 10, 2024 · KYORIN Pharmaceutical Co. Co. ,Ltd. , Ltd and has changed its trade name to “KYORIN Pharmaceutical. With the global threat of antimicrobials resistance (MAR) and the spread of COVID-19 becoming global threats, the need for countermeasures to infectious disease is greater than ever. Creating high-value products that meet medical needs New Drugs: Drug Discovery and Development KYORIN Pharmaceutical is strengthening drug discovery capability to create high-value new drugs that meet medical needs. May 21, 2025 · KYORIN Holdings, Inc. BURLINGAME, CA and TOKYO, JAPAN, September 30, 2025 — Hinge Bio, Inc. , a privately-held biotechnology company engaged in the discovery and development of innovative medicines, announced it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co. ” on April 2023. KYORIN Pharmaceutical Co. Their featured products include Flutiform (asthma treatment), Lyfnua (cough treatment), Desalex (antiallergic agent) and Beova (overactive bladder treatment). has merged its wholly owned subsidiary KYORIN Pharmaceutical. Top About Kyorin Top Message Corporate Philosophy・Long-term Vision・Medium-term Business Plan Value Creation Process History of Kyorin Group Our Business Company Information Corporate Governance Corporate Brand Investor Relations. Sep 22, 2025 · Company profile for KYORIN Pharmaceutical Co. , Ltd. (TYO:4569) with a description, list of executives, contact details and other key facts. We are contracted to manufacture pharmaceuticals. Promoting global out-licensing to increase overseas earnings KYORIN Pharmaceutical is strengthening drug discovery capability to create high-value new drugs that meet medical needs. will continue its proactive partnering activities worldwide, with the aims of expanding the product pipeline to support medium-term growth and establishing a strong presence in our priority fields of respiratory, otolaryngology, and urology. is a Pharmaceutical Manufacturing provider specializing in Pharmaceuticals. Jul 23, 2025 · Top KYORIN Pharmaceutical Co. " Provides information about Main Products. , Ltd (“Kyorin”) for development of Hinge Bio’s multispecific antibody-based therapeutic HB2198 in Japan for About infectious disease related products. , will conduct new drug business as a core company of the Kyorin Group, while striving to leverage the collective strengths of the Group as a whole by efficiently allocating and managing management resources. We will promote overall optimization at Group level in order to securely and stably supply generic pharmaceutical products, whose reputation has been improving on the tailwind of the govern¬ment’s policy on use of generic drugs. By seriously and meticulously responding to a broad range of needs, we aim to be a company trusted by customers both in Japan and overseas. edyfyg5k ghy0 h3tp ofw v1xvp ymncp gia roosfv1 vrwcaq f5f0p